Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.65%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.39 per share when it actually produced a loss of $0.37, delivering a surprise of +5.13%.Over the last four quarters, the ...